Loading publications…
The last 5 uploaded publications
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. , 183, DOI: https://doi.org/10.1016/j.ejca.2023.01.016.
Article62 days agoReal-world outcomes of immunosuppressed patients with Merkel cell carcinoma treated with immune checkpoint inhibitors.
William Mullally, Andrew S. Brohl, Aisha Ghaus, Mark Shackleton, Yang Wang, Shahneen Sandhu, Jürgen Becker, Marcin Dzienis, Liam Dwyer, Jenny Lee, Adnan Khattak, Lydia Warburton, Christopher Steer, Wen Xu (2025). Real-world outcomes of immunosuppressed patients with Merkel cell carcinoma treated with immune checkpoint inhibitors.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.9587.
Article62 days agoNiraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R. Smith, Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Olof Ståhl, David Olmos, Daniel C. Danila, Gary Mason, Byron M. Espina, Xin Zhao, Karen A. Urtishak, Peter Francis, Angela Lopez‐Gitlitz, Karim Fizazi, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, T. J. Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean‐Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fábio Franke, Fabrício Augusto Martinelli de Oliveira, Andrea Juliana Gomes, Hélio Pinczowski, Daniel D’Almeida Preto, Luis Eduardo Rosa Zucca, Giuliano Santos Borges, André M. Murad, Fred Saad, Kim N., Yves Fradet, Neil Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stéphane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean‐Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz‐Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus Johannes Maria van den Eertwegh, Johannes Voortman, Maureen J.B. Aarts, Jourik A. Gietema, Choung‐Soo Kim, Young Deuk Choi, Byung Ha Chung, Rustem Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, Pablo Maroto, Jesús García-Donás, Juan F. Rodríguez-Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, D. Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente, E.A. Castellanos Abella, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich, René Blom (2022). Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. , 23(3), DOI: https://doi.org/10.1016/s1470-2045(21)00757-9.
Article62 days agoNiraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Olof Ståhl, David Olmos, Daniel C. Danila, Gary Mason, Byron M. Espina, Xin Zhao, Karen A. Urtishak, Peter Francis, Angela Lopez‐Gitlitz, Karim Fizazi, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, T. J. Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean‐Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fábio Franke, Fabrício Augusto Martinelli de Oliveira, Andrea Juliana Gomes, Hélio Pinczowski, Daniel D’Almeida Preto, Luis Eduardo Rosa Zucca, Giuliano Santos Borges, André M. Murad, Fred Saad, Kim N., Yves Fradet, Neil Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stéphane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean‐Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz‐Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus Johannes Maria van den Eertwegh, Johannes Voortman, Maureen J.B. Aarts, Jourik A. Gietema, Choung‐Soo Kim, Young Deuk Choi, Byung Ha Chung, Rustem Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, Pablo Maroto, Jesús García-Donás, Juan F. Rodríguez-Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, D. Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente, E.A. Castellanos Abella, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich, René Blom, Matthew R. Smith, Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara (2022). Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. , 23(3), DOI: https://doi.org/10.1016/s1470-2045(21)00757-9.
Article62 days agoDurability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.
Georgina V. Long, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu, Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino (2021). Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.. , 39(15_suppl), DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.9543.
Article62 days ago